SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc.
(Nasdaq: INBX), announced the appointment of three key executives:
David Matly, M.B.A., as Chief
Commercial Officer; David Kao,
PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and
Jack Tsai, M.D., M.B.A., as Vice
President of Business Development.
"The additions of David, David and Jack come at an important
time for Inhibrx, as our pipeline demonstrates meaningful clinical
activity in areas of high unmet medical need such as Alpha-1
Antitrypsin Deficiency and Chondrosarcoma. We are building a
seasoned, world-class leadership team to progress toward our first
regulatory approvals and commercial readiness. Together,
these strategic hires bring a wealth of expertise and business
acumen that complements our executive management team and
strengthens the future trajectory of the company," said Mark
Lappe, Chief Executive Officer and Co-founder of Inhibrx.
Inhibrx also announced the appointment of Kristiina Vuori, M.D., Ph.D. to its Board of
Directors, effective October 28,
2021. Dr. Vuori will serve as a member of the Audit
Committee and Nominating and Governance Committee of the Board.
In connection with this appointment, Inhibrx Chief Scientific
Officer and Co-founder, Brendan
Eckelman, Ph.D., stepped down from the Board.
"We are pleased to welcome Kristiina to our Board of Directors,"
said Mr. Lappe "Inhibrx will benefit from the skills and
expertise Kristiina brings as an accomplished leader and
researcher."
Mr. Lappe added, "I would also like to thank Brendan for his
service on our Board. He will continue to drive our research
strategy and execution and be an integral part of the executive
team."
David Matly, Chief
Commercial Officer
Mr. Matly brings extensive commercial
launch and leadership experience across both orphan diseases and
oncology. Mr. Matly joins us from Novartis where he served as the
global Vice President of the MDS/AML franchise, one of the largest
potential growth areas of Novartis Oncology, leading the launch
preparation of their flagship program, as well as ensuring
commercial success of the entire AML/MDS portfolio. Prior to this
role, Mr. Matly was the global commercial lead of the sickle cell
disease therapeutic area, leading the launch of ADAKVEO, which at
the time was the first approved novel therapy in almost two
decades. Also, at Novartis, Mr. Matly was the global
commercial lead of PROMACTA/REVOLADE, the largest growth driver of
Novartis Oncology. Mr. Matly began his career at Eli Lilly,
holding several positions of increasing responsibility in sales and
marketing, most notably leading the US launch of CYRAMZA in
metastatic lung cancer.
Mr. Matly received his B.S. in Industrial Engineering from
Purdue University and his M.B.A. from
Harvard Business School.
David Kao, Vice President
of Regulatory Affairs
Dr. Kao brings over 20 years
of pharmaceutical industry experience in drug development,
overseeing programs from initial IND submission to marketing
registration and life-cycle management. Prior to Inhibrx, Dr. Kao
served as a regulatory lead collaborating on the design of
integrated development strategies to support global registration
for novel therapies in the oncology, immunology, neurology and
cardiovascular therapeutic areas. He comes with considerable
regulatory experience in the management of complex clinical
programs and in the preparation of regulatory marketing
applications from global organizations including Eisai, Roche,
Daiichi-Sankyo and Celgene. He most recently served as Development
Program Leader at BMS, responsible for the successful delivery of
all aspects of drug development for a specific immunology
project.
Dr. Kao is a registered Pharmacist and received his B.S. in
Pharmacy from Rutgers University,
M.B.A. in Marketing from Rutgers Business School, and PharmD from
Shenandoah University.
Jack Tsai, Vice President
of Business Development
Dr. Tsai leads our business
development, portfolio strategy, and formation of new business
ventures. He is a seasoned executive that brings more than 15
years of oncology leadership and biopharma industry expertise in
business development, search and evaluation, marketing, and new
product planning. While at Sanofi, Genzyme and Takeda, Dr. Tsai
was responsible for licensing deals and acquisitions with an
aggregate value of over $2 billion.
His role included activities that resulted in global co-development
programs, worldwide collaborative commercialization, while also
enabling the transition of innovative early-stage research to
late-stage development. He has an outstanding track record of
bringing novel treatment modalities to patients, including
immuno-oncology therapies that have changed cancer
treatment.
Dr. Tsai holds an M.D. from Tufts
University School of Medicine and serves as a member of its
faculty, where for over a decade he has been teaching medical
student curricula on clinical and integrative medicine. He
received his M.B.A. from MIT Sloan School of
Management, and his B.S. in Molecular Genetics from the
University of Rochester.
Kristiina Vuori,
Director
Since January
2010, Dr. Vuori has served as President of, and has held the
Pauline and Stanley Foster Presidential Chair at, Sanford Burnham
Prebys Medical Discovery Institute (the "Institute"), a non-profit
research organization with major research programs in cancer,
neurodegeneration, diabetes, and infectious, inflammatory, and
childhood diseases. Dr. Vuori also served as the Institute's
interim Chief Executive Officer from January
2013 to September 2014, and
from September 2017 to June 2020. Since January
1995, Dr. Vuori has served as a Professor at the Institute's
National Cancer Institute-designated Cancer Center, an
interdisciplinary basic and translational research effort
mobilizing over 400 scientists.
Dr. Vuori has previously served or is currently serving on the
Board of Directors of Bionano Genomics, Inc., Sio Gene Therapies,
Forian, Inc., the American Association for Cancer Research, the
California Institute for Regenerative Medicine, the California
Breast Cancer Research Council and WebMD. Dr. Vuori received her
M.D. and Ph.D. from the University of Oulu, Finland.
About Inhibrx, Inc.
Inhibrx is a clinical-stage
biotechnology company focused on developing a broad pipeline of
novel biologic therapeutic candidates in oncology and orphan
diseases. Inhibrx utilizes diverse methods of protein engineering
to address the specific requirements of complex target and disease
biology, including its proprietary sdAb platform. Inhibrx has
collaborations with 2seventy bio, Bristol-Myers Squibb and Chiesi.
For more information, please visit www.inhibrx.com.
Forward-Looking Statements
Inhibrx cautions you that
statements contained in this press release regarding matters that
are not historical facts are forward-looking statements. These
statements are based on Inhibrx's current beliefs and expectations.
Such forward-looking statements include, but are not limited to,
those regarding the expected benefits of Dr. Vuori's service on the
Board of Directors of Inhibrx or any potential benefit as a result
of the addition of Mr. Matly, Dr. Kao and Dr. Tsai to the
management team as well as the Company's plans for growth and
advancement of its programs. Actual results may differ from those
set forth in this press release due to the risks and uncertainties
inherent in Inhibrx's business, including, without limitation,
risks and uncertainties regarding: the initiation, timing, progress
and results of its preclinical studies and clinical trials, and its
research and development programs; its ability to advance
therapeutic candidates into, and successfully complete, clinical
trials; its interpretation of initial, interim or preliminary data
from its clinical trials, including interpretations regarding
disease control and disease response; the timing or likelihood of
regulatory filings and approvals; the successful commercialization
of its therapeutic candidates, if approved; the pricing, coverage
and reimbursement of its therapeutic candidates, if approved; its
ability to utilize its technology platform to generate and advance
additional therapeutic candidates; the implementation of its
business model and strategic plans for its business and therapeutic
candidates; its ability to successfully manufacture therapeutic
candidates for clinical trials and commercial use, if approved; its
ability to contract with third-party suppliers and manufacturers
and their ability to perform adequately; the scope of protection it
is able to establish and maintain for intellectual property rights
covering its therapeutic candidates; its ability to enter into
strategic partnerships and the potential benefits of these
partnerships; its estimates regarding expenses, capital
requirements and needs for additional financing and financial
performance; its expectations regarding the impact of the COVID-19
pandemic on its business; and other risks described from time to
time in the "Risk Factors" section of our filings with the U.S.
Securities and Exchange Commission, including those described in
our Annual Report on Form 10-K as well as our Quarterly Reports on
Form 10-Q, and supplemented from time to time by our Current
Reports on Form 8-K. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof, and Inhibrx undertakes no obligation to update these
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. This press release contains estimates and other
statistical data made by independent parties and by Inhibrx. This
data involves a number of assumptions and limitations, and you are
cautioned not to give undue weight to such estimates.
Investor and Media Contact:
Kelly Deck, CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-strengthens-leadership-team-with-three-key-executive-hires-and-announces-appointment-of-kristiina-vuori-md-phd-to-its-board-of-directors-301410893.html
SOURCE Inhibrx Inc.